Researchers assessed whether pre-existing antibodies to influenza, which are shaped by early infection and subsequent exposures, impact children’s responses to influenza vaccination.
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
Investigators conducted a randomized, open-label trial during the 2018-2019 influenza season to assess neutralization titers in pre- and post-immunization sera from 133 adults immunized with one of three types of influenza vaccines.